Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Association of the Adipokine Zinc-Alpha2-Glycoprotein With Non-Alcoholic Fatty Liver Disease and Related Risk Factors: A Comprehensive Systematic Review Publisher Pubmed



Namkhah Z1 ; Naeini F1 ; Ostadrahimi A2 ; Tutunchi H2 ; Hosseinzadehattar MJ1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Science, Tehran, Iran
  2. 2. Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition & Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran

Source: International Journal of Clinical Practice Published:2021


Abstract

Background and aim: The adipokine zinc-alpha2-glycoprotein (ZAG), a multidisciplinary protein, is involved in lipid metabolism, glucose homeostasis and energy balance. Accumulating evidence demonstrates that the expression of ZAG is mainly downregulated in obesity and obesity-related conditions. In the present study, we assessed the association of ZAG with non-alcoholic fatty liver disease (NAFLD) and the related risk factors including obesity, metabolic factors and inflammatory parameters, with emphasis on potential mechanisms underlying these associations. Methods: PRISMA guidelines were followed in this review. Systematic searches were performed using the PubMed/Medline, ScienceDirect, Scopus, EMBASE, ProQuest and Google Scholar databases, up to August 2020 for all relevant published papers. Results: Out of 362 records screened, 34 articles were included in the final analysis. According to the studies reviewed here, ZAG appears to exert a protective effect against NAFLD by enhancing mRNA expression levels of peroxisome proliferator-activated receptor α (PPARα) and PPARγ, promoting mRNA expression levels of the lipolysis-related genes, reducing mRNA expression levels of the lipogenesis-related genes, increasing hepatic fatty acid oxidation, ameliorating hepatic steatosis, promoting the activity of brown adipose tissue and the expression of thermogenesis-related genes, modulating energy balance and glucose homeostasis, and elevating plasma levels of healthy adipokines such as adiponectin. ZAG can also be involved in the regulation of inflammatory responses by attenuation of the expression of pro-inflammatory and pro-fibrotic mediators. Conclusion: According to the studies reviewed here, ZAG is suggested to be a promising therapeutic target for NAFLD. However, the favourable effects of ZAG need to be confirmed in prospective cohort studies. © 2021 John Wiley & Sons Ltd
Related Docs
View other Related Docs
1. Comparative Assessment of Serum Adipokines Zinc-Α2-Glycoprotein and Adipose Triglyceride Lipase, and Cardiovascular Risk Factors Between Normal Weight and Obese Patients With Hemodialysis, Archives of Medical Research (2017)
2. The Relationship of Serum Adipokines With Malnutrition Inflammation Score in Haemodialysis, European Journal of Clinical Investigation (2017)
3. The Relationship Between Serum Adipokines and Glucose Homeostasis in Normal-Weight and Obese Patients on Hemodialysis: A Preliminary Study, International Urology and Nephrology (2020)
4. Does Naringenin Supplementation Improve Lipid Profile, Severity of Hepatic Steatosis and Probability of Liver Fibrosis in Overweight/Obese Patients With Nafld? a Randomised, Double-Blind, Placebo-Controlled, Clinical Trial, International Journal of Clinical Practice (2021)
5. A Comprehensive Systematic Review of the Effects of Naringenin, a Citrus-Derived Flavonoid, on Risk Factors for Nonalcoholic Fatty Liver Disease, Advances in Nutrition (2021)
6. The Association Between Dietary Diversity Score and Odds of Nonalcoholic Fatty Liver Disease: A Case-Control Study, European Journal of Gastroenterology and Hepatology (2022)
7. Advancing the Global Public Health Agenda for Nafld: A Consensus Statement, Nature Reviews Gastroenterology and Hepatology (2022)
8. Effects of Naringenin Supplementation in Overweight/Obese Patients With Non-Alcoholic Fatty Liver Disease: Study Protocol for a Randomized Double-Blind Clinical Trial, Trials (2021)
Experts (# of related papers)
View all Related Experts
Mohammad Javad Hosseinzadeh Attar (7)
Mehdi Yaseri (4)
Other Related Docs
9. Lean Individual's Non-Alcoholic Fatty Liver Disease: A Review Article; [بیماري کبد چرب غیرالکلی در افراد لاغر: یک مقاله مروري], Tehran University Medical Journal (2022)
10. Sglt2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and Nafld, Endocrinology (United States) (2021)
11. Oleoylethanolamide Supplementation in Obese Patients Newly Diagnosed With Non-Alcoholic Fatty Liver Disease: Effects on Metabolic Parameters, Anthropometric Indices, and Expression of Ppar-Α, Ucp1, and Ucp2 Genes, Pharmacological Research (2020)
12. Changes of Insulin Resistance and Adipokines Following Supplementation With Glycyrrhiza Glabra L. Extract in Combination With a Low-Calorie Diet in Overweight and Obese Subjects: A Randomized Double Blind Clinical Trial, Advanced Pharmaceutical Bulletin (2018)
13. The Effects of Green Cardamom on Blood Glucose Indices, Lipids, Inflammatory Factors, Paraxonase-1, Sirtuin-1, and Irisin in Patients With Nonalcoholic Fatty Liver Disease and Obesity: Study Protocol for a Randomized Controlled Trial, Trials (2017)
14. The Association Between Major Dietary Patterns With the Risk of Non-Alcoholic Fatty Liver Disease, Oxidative Stress and Metabolic Parameters: A Case–Control Study, Journal of Diabetes and Metabolic Disorders (2022)
15. The Pathophysiological Associations Between Obesity, Nafld, and Atherosclerotic Cardiovascular Diseases, Hormone and Metabolic Research (2024)
16. The Effects of Curcumin Supplementation on Liver Enzymes, Lipid Profile, Glucose Homeostasis, and Hepatic Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease, European Journal of Clinical Nutrition (2019)
17. Effects of Oleoylethanolamide Supplementation on Atherogenic Indices and Hematological Parameters in Patients With Nonalcoholic Fatty Liver Disease: A Clinical Trial, Health Promotion Perspectives (2020)
18. Effects of Gut Microbial Therapy on Lipid Profile in Individuals With Non-Alcoholic Fatty Liver Disease: An Umbrella Meta-Analysis Study, Systematic Reviews (2023)
19. Green Cardamom Increases Sirtuin-1 and Reduces Inflammation in Overweight or Obese Patients With Non-Alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Clinical Trial, Nutrition and Metabolism (2018)
20. Serum Neuregulin 4 (Nrg-4) Level and Non-Alcoholic Fatty Liver Disease (Nafld): A Case-Control Study, International Journal of Clinical Practice (2021)
21. Effects of Calorie Restricted Diet on Oxidative/Antioxidative Status Biomarkers and Serum Fibroblast Growth Factor 21 Levels in Nonalcoholic Fatty Liver Disease Patients: A Randomized, Controlled Clinical Trial, Nutrients (2022)
22. Efficacy of Nanocurcumin Supplementation on Insulin Resistance, Lipids, Inflammatory Factors and Nesfatin Among Obese Patients With Non-Alcoholic Fatty Liver Disease (Nafld): A Trial Protocol, BMJ Open (2017)
23. Atherogenic Index of Plasma Is an Independent Predictor of Metabolic-Associated Fatty Liver Disease in Patients With Type 2 Diabetes, European Journal of Medical Research (2022)
24. Antibody Development to Hcv Alternate Reading Frame Protein in Liver Transplant Candidate and Its Computational Analysis, Current Proteomics (2020)
25. Effects of Oleoylethanolamide Supplementation on Inflammatory Biomarkers, Oxidative Stress and Antioxidant Parameters of Obese Patients With Nafld on a Calorie-Restricted Diet: A Randomized Controlled Trial, Frontiers in Pharmacology (2023)
26. Fibrosis Score 4 Index Has an Independent Relationship With Coronary Artery Diseases in Patients With Metabolic-Associated Fatty Liver Disease, Diabetology and Metabolic Syndrome (2023)
27. The Role of Gut Microbiota in Non-Alcoholic Fatty Liver Disease Pathogenesis, Obesity Medicine (2024)
28. Nomenclature and Definition of Metabolic-Associated Fatty Liver Disease: A Consensus From the Middle East and North Africa, The Lancet Gastroenterology and Hepatology (2021)
29. A Randomized Triple-Blind Controlled Clinical Trial Evaluation of Sitagliptin in the Treatment of Patients With Non-Alcoholic Fatty Liver Diseases Without Diabetes, Frontiers in Medicine (2022)
30. Dietary Inflammatory Potential and Metabolic (Dysfunction)-Associated Steatotic Liver Disease and Its Complications: A Comprehensive Review, Clinical Nutrition ESPEN (2025)
31. Hesperidin Improves Hepatic Steatosis, Hepatic Enzymes, and Metabolic and Inflammatory Parameters in Patients With Nonalcoholic Fatty Liver Disease: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial, Phytotherapy Research (2019)
32. The Obesity-Autophagy-Cancer Axis: Mechanistic Insights and Therapeutic Perspectives, Seminars in Cancer Biology (2024)
33. Prevalence and Characteristics of Metabolic Dysfunction-Associated Fatty Liver Disease Among an Iranian Adult Population With Ethnic and Genetic Diversity: Results of the Polyiran-Liver Study, Middle East Journal of Digestive Diseases (2024)
34. Curcumin and Inflammation in Non-Alcoholic Fatty Liver Disease: A Randomized, Placebo Controlled Clinical Trial, BMC Gastroenterology (2019)